These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 30340460)

  • 41. Early intervention with almotriptan improves sustained pain-free response in acute migraine.
    Mathew NT
    Headache; 2003; 43(10):1075-9. PubMed ID: 14629242
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of neurostimulation in migraine.
    Grazzi L; Padovan A; Barbanti P
    Neurol Sci; 2015 May; 36 Suppl 1():121-3. PubMed ID: 26017526
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correction to: Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial.
    Grazzi L; Tassorelli C; de Tommaso M; Pierangeli G; Martelletti P; Rainero I; Geppetti P; Ambrosini A; Sarchielli P; Liebler E; Barbanti P;
    J Headache Pain; 2019 Jan; 20(1):1. PubMed ID: 30616570
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered
    Silberstein S; Winner PK; McAllister PJ; Tepper SJ; Halker R; Mahmoud RA; Siffert J
    Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patient experience with non-invasive vagus nerve stimulator: gammaCore patient registry.
    Mwamburi M; Liebler EJ; Staats PS
    Am J Manag Care; 2020 Feb; 26(1 Suppl):S15-S19. PubMed ID: 32109020
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vagus Nerve Stimulation and Headache.
    Yuan H; Silberstein SD
    Headache; 2017 Apr; 57 Suppl 1():29-33. PubMed ID: 26473407
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of different non-pharmacologic placebo treatments on migraine prevention: a network meta-analysis of randomized controlled trials.
    Huang YB; Yuan L; Xiao XY; Wang XY; Feng SJ; Zheng H
    Acta Neurol Belg; 2024 Aug; 124(4):1125-1139. PubMed ID: 38245660
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Non-invasive vagus nerve stimulation for primary headache: A clinical update.
    Silberstein SD; Yuan H; Najib U; Ailani J; Morais AL; Mathew PG; Liebler E; Tassorelli C; Diener HC
    Cephalalgia; 2020 Oct; 40(12):1370-1384. PubMed ID: 32718243
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized, double-blind, sham-controlled PREMIUM II trial.
    Najib U; Smith T; Hindiyeh N; Saper J; Nye B; Ashina S; McClure CK; Marmura MJ; Chase S; Liebler E; Lipton RB
    Cephalalgia; 2022 Jun; 42(7):560-569. PubMed ID: 35001643
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness analysis of non-invasive vagus nerve stimulation for the treatment of chronic cluster headache.
    Morris J; Straube A; Diener HC; Ahmed F; Silver N; Walker S; Liebler E; Gaul C
    J Headache Pain; 2016; 17():43. PubMed ID: 27102120
    [TBL] [Abstract][Full Text] [Related]  

  • 51. External Trigeminal Nerve Stimulation for the Acute Treatment of Migraine: Open-Label Trial on Safety and Efficacy.
    Chou DE; Gross GJ; Casadei CH; Yugrakh MS
    Neuromodulation; 2017 Oct; 20(7):678-683. PubMed ID: 28580703
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Non-invasive vagus nerve stimulation in a hungry state decreases heart rate variability.
    Altınkaya Z; Öztürk L; Büyükgüdük İ; Yanık H; Yılmaz DD; Yar B; Değirmenci E; Dal U; Veldhuizen MG
    Physiol Behav; 2023 Jan; 258():114016. PubMed ID: 36334796
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Non-Invasive Neuromodulation for the Treatment of Migraine and Cluster Headache].
    Danno D
    Brain Nerve; 2021 Apr; 73(4):339-346. PubMed ID: 33824221
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of non-invasive vagus nerve stimulation on clinical symptoms and molecular biomarkers in Parkinson's disease.
    Mondal B; Choudhury S; Banerjee R; Roy A; Chatterjee K; Basu P; Singh R; Halder S; Shubham S; Baker SN; Baker MR; Kumar H
    Front Aging Neurosci; 2023; 15():1331575. PubMed ID: 38384731
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Non-invasive neuromodulation for migraine and cluster headache: a systematic review of clinical trials.
    Reuter U; McClure C; Liebler E; Pozo-Rosich P
    J Neurol Neurosurg Psychiatry; 2019 Jul; 90(7):796-804. PubMed ID: 30824632
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy profile of noninvasive vagus nerve stimulation on cortical spreading depression susceptibility and the tissue response in a rat model.
    Liu TT; Morais A; Takizawa T; Mulder I; Simon BJ; Chen SP; Wang SJ; Ayata C; Yen JC
    J Headache Pain; 2022 Jan; 23(1):12. PubMed ID: 35062860
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and tolerability of adjunct non-invasive vagus nerve stimulation in people with parkinson's: a study protocol.
    Sigurdsson HP; Hunter H; Alcock L; Wilson R; Pienaar I; Want E; Baker MR; Taylor JP; Rochester L; Yarnall AJ
    BMC Neurol; 2023 Feb; 23(1):58. PubMed ID: 36737716
    [TBL] [Abstract][Full Text] [Related]  

  • 58. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.
    Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
    Headache; 2018 May; 58(5):676-687. PubMed ID: 29878341
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial.
    Lipton RB; Dodick DW; Silberstein SD; Saper JR; Aurora SK; Pearlman SH; Fischell RE; Ruppel PL; Goadsby PJ
    Lancet Neurol; 2010 Apr; 9(4):373-80. PubMed ID: 20206581
    [TBL] [Abstract][Full Text] [Related]  

  • 60. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.
    Tepper SJ; Cady RK; Silberstein S; Messina J; Mahmoud RA; Djupesland PG; Shin P; Siffert J
    Headache; 2015 May; 55(5):621-35. PubMed ID: 25941016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.